The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > BUSINESS
BUSINESS
- Biogen Japan, Eisai to End MS Copromotion Pact in Japan
March 3, 2023
- Neil MacGregor Takes Over as President of Amgen Japan
March 2, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Eylea 8 mg Filed in Japan to Extend Dosing Intervals: Bayer
March 2, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- AstraZeneca Files Anti-RSV Antibody Nirsevimab in Japan
March 1, 2023
- Nippon Chemiphar Out-Licenses XOR Inhibitor to Chinese Pharma
March 1, 2023
- UCB Japan Files Rozanolixizumab for Generalized Myasthenia Gravis
March 1, 2023
- Ono Seeks Japan Nod for Malignant Mesothelioma for Opdivo
March 1, 2023
- Actemra Filed in Japan for CRS Induced by Cancer Treatment: Chugai
March 1, 2023
- Lecanemab Earns Priority Review Status in China: Eisai
March 1, 2023
- Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- Enhertu Approved in China for HER2 Positive Breast Cancer
February 28, 2023
- COVID-19 Drugs Haul Big Sales in 2022, Veklury Crosses 100 Billion Yen Line
February 27, 2023
- Pfizer Japan Files PARP Inhibitor Talazoparib for Breast and Prostate Cancer
February 27, 2023
- Astellas Presents Update on PI/II Study of AT845 for Late-Onset Pompe Disease
February 27, 2023
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Ono Bags Right to Cue Biopharma’s Tregs-Inducing Bispecific Protein
February 24, 2023
ページ
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…